Pharmacy chain CVS won US antitrust approval for its US69 billion acquisition of health insurer Aetna, the Justice Department announced on Wednesday, October 10, reported the Washington Post.
The merger can go ahead as long as Aetna sells off its private Medicare drug plans, the Justice Department said. The tie-up will allow CVS, whose retail pharmacy business serves 5 million customers a day, to turn more of its brick-and-mortar locations into front-line clinics for basic medical services and patient monitoring.
“Our focus will be at the local and community level,” CVS CEO Larry Merlo said, “taking advantage of our thousands of locations and touchpoints throughout the country to intervene with consumers to help predict and prevent potential health problems before they occur.”
According to the Post, the Aetna acquisition is also expected to give CVS more leverage in its negotiations with drugmakers over drug prices, analysts say.
This merger would combine the third-largest health insurer and the largest national pharmacy chain, but has come under fire from the Association of American Physicians and Surgeons.
Full Content: The Washington Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI